SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.530
+0.060 (1.73%)
At close: Apr 28, 2026, 4:00 PM EDT
3.500
-0.030 (-0.85%)
After-hours: Apr 28, 2026, 6:20 PM EDT
SAB Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | 1.32 | 2.24 | 23.9 | 60.88 | |
| Revenue Growth (YoY) | - | -40.94% | -90.63% | -60.73% | 10.21% | |
| Cost of Revenue | 33.35 | 29.55 | 16.52 | 36.44 | 57.18 | |
| Gross Profit | -33.35 | -28.23 | -14.28 | -12.53 | 3.69 | |
| Selling, General & Admin | 15.6 | 14.68 | 23.8 | 16.38 | 17.09 | |
| Operating Expenses | 15.6 | 14.68 | 23.8 | 16.38 | 17.09 | |
| Operating Income | -48.95 | -42.91 | -38.08 | -28.92 | -13.39 | |
| Interest Expense | -0.24 | -0.32 | -0.32 | -0.3 | -0.29 | |
| Interest & Investment Income | 1.43 | 1.29 | 0.58 | 0.07 | 0.02 | |
| Other Non Operating Income (Expenses) | 61.04 | 7.84 | -4.39 | 10.38 | -4.15 | |
| EBT Excluding Unusual Items | 13.27 | -34.11 | -42.19 | -18.76 | -17.81 | |
| Gain (Loss) on Sale of Assets | - | - | - | 0.02 | - | |
| Other Unusual Items | - | - | - | 0.03 | 0.67 | |
| Pretax Income | 13.27 | -34.11 | -42.19 | -18.72 | -17.14 | |
| Income Tax Expense | - | - | - | 0.03 | - | |
| Net Income | 13.27 | -34.11 | -42.19 | -18.74 | -17.14 | |
| Preferred Dividends & Other Adjustments | 9.01 | - | - | - | - | |
| Net Income to Common | 4.26 | -34.11 | -42.19 | -18.74 | -17.14 | |
| Shares Outstanding (Basic) | 19 | 9 | 6 | 4 | 3 | |
| Shares Outstanding (Diluted) | 61 | 9 | 6 | 4 | 3 | |
| Shares Change (YoY) | 562.28% | 67.74% | 26.86% | 59.20% | 1.21% | |
| EPS (Basic) | 0.22 | -3.68 | -7.64 | -4.31 | -6.27 | |
| EPS (Diluted) | -0.79 | -3.68 | -7.64 | -4.31 | -6.30 | |
| Free Cash Flow | -45.71 | -34.63 | -25.32 | -25.63 | -8.96 | |
| Free Cash Flow Per Share | -0.74 | -3.74 | -4.58 | -5.89 | -3.28 | |
| Gross Margin | - | - | - | -52.44% | 6.07% | |
| Operating Margin | - | -3244.87% | -1700.56% | -120.97% | -22.00% | |
| Profit Margin | - | -2579.03% | -1884.50% | -78.40% | -28.16% | |
| Free Cash Flow Margin | - | -2618.65% | -1130.71% | -107.20% | -14.71% | |
| EBITDA | -45.87 | -38.12 | -34.33 | -25.63 | -11.9 | |
| EBITDA Margin | - | - | - | -107.20% | -19.55% | |
| D&A For EBITDA | 3.08 | 4.79 | 3.75 | 3.29 | 1.49 | |
| EBIT | -48.95 | -42.91 | -38.08 | -28.92 | -13.39 | |
| EBIT Margin | - | - | - | -120.97% | -22.00% | |
| Revenue as Reported | - | 1.32 | 2.24 | 23.9 | 60.88 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.